Ruth Seggewiss‐Bernhardt

1.5k total citations · 1 hit paper
19 papers, 889 citations indexed

About

Ruth Seggewiss‐Bernhardt is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Ruth Seggewiss‐Bernhardt has authored 19 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Ruth Seggewiss‐Bernhardt's work include Immune Cell Function and Interaction (8 papers), CAR-T cell therapy research (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Ruth Seggewiss‐Bernhardt is often cited by papers focused on Immune Cell Function and Interaction (8 papers), CAR-T cell therapy research (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Ruth Seggewiss‐Bernhardt collaborates with scholars based in Germany, United States and Switzerland. Ruth Seggewiss‐Bernhardt's co-authors include Dejan Juric, Martin Schüler, Cornelia Quadt, Douglas Bootle, David Demanse, José Baselga, Marta Gil-Martín, Lars Blumenstein, Filip Jankú and Alan Huang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Ruth Seggewiss‐Bernhardt

18 papers receiving 876 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruth Seggewiss‐Bernhardt Germany	12	434	409	232	214	152	19	889
K. Papadopoulos United States	16	598 1.4×	540 1.3×	215 0.9×	299 1.4×	90 0.6×	56	1.1k
Analía Azaro Spain	18	569 1.3×	557 1.4×	295 1.3×	152 0.7×	104 0.7×	56	1.1k
R. Stahel Switzerland	18	447 1.0×	582 1.4×	369 1.6×	243 1.1×	117 0.8×	68	1.2k
KyungMann Kim United States	15	308 0.7×	552 1.3×	127 0.5×	309 1.4×	75 0.5×	22	1.1k
Josep Lluís Parra United Kingdom	5	798 1.8×	352 0.9×	152 0.7×	99 0.5×	121 0.8×	6	1.1k
Stephen Castaneda United States	10	217 0.5×	356 0.9×	143 0.6×	146 0.7×	96 0.6×	14	685
Valérie Méresse France	13	314 0.7×	335 0.8×	103 0.4×	117 0.5×	133 0.9×	23	830
Ivan Inigo United States	10	225 0.5×	363 0.9×	110 0.5×	160 0.7×	112 0.7×	21	693
H. David Inzunza United States	8	225 0.5×	798 2.0×	156 0.7×	483 2.3×	75 0.5×	12	1.0k
Jean Powers Canada	9	420 1.0×	330 0.8×	265 1.1×	81 0.4×	69 0.5×	12	748

Countries citing papers authored by Ruth Seggewiss‐Bernhardt

Since Specialization

Citations

This map shows the geographic impact of Ruth Seggewiss‐Bernhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Seggewiss‐Bernhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Seggewiss‐Bernhardt more than expected).

Fields of papers citing papers by Ruth Seggewiss‐Bernhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Seggewiss‐Bernhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Seggewiss‐Bernhardt. The network helps show where Ruth Seggewiss‐Bernhardt may publish in the future.

Co-authorship network of co-authors of Ruth Seggewiss‐Bernhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Seggewiss‐Bernhardt. A scholar is included among the top collaborators of Ruth Seggewiss‐Bernhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Seggewiss‐Bernhardt. Ruth Seggewiss‐Bernhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Schalk, Enrico, Boris Böll, Nicola Giesen, et al.. (2024). Sex-Disaggregated Analysis of Central Venous Catheter-Related Bloodstream Infections in Patients with Cancer. Oncology Research and Treatment. 48(1-2). 1–10.

Hager, Benjamin, et al.. (2021). Roboterassistierte Harnblasendivertikelresektion (RAHDR). Aktuelle Urologie. 53(3). 254–261. 1 indexed citations

Stöhr, Robert, Lars Tögel, Florian Fuchs, et al.. (2021). MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting. Cancers. 13(19). 5023–5023. 22 indexed citations

Hager, Benjamin, et al.. (2020). Ein seltener Fall eines renalen ektopen Schilddrüsengewebes. Aktuelle Urologie. 52(1). 64–66. 1 indexed citations

Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →

Juric, Dejan, Filip Jankú, Jordi Rodón, et al.. (2018). Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer. JAMA Oncology. 5(2). e184475–e184475. 186 indexed citations

Lohmeyer, Jürgen, et al.. (2018). Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner. Clinical & Experimental Immunology. 193(1). 64–72. 23 indexed citations

Kebenko, Maxim, M. Wolf, Annette Hasenburg, et al.. (2018). A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. OncoImmunology. 7(8). e1450710–e1450710. 138 indexed citations

Nerreter, Thomas, et al.. (2017). Robust 8-color flow cytometry panel reveals enhanced effector function of NKG2C+ CD57+ FcεRγ− NK cells in CMV seropositive human blood donors. Immunobiology. 222(5). 719–725. 4 indexed citations

10.

Veluchamy, John P., Nina Kok, Ruth Seggewiss‐Bernhardt, et al.. (2017). Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. Scientific Reports. 7(1). 43873–43873. 21 indexed citations

11.

Hausmann, Stefan, Evelyn R. Brandt, Hermann Einsele, et al.. (2015). Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines. PLoS ONE. 10(4). e0122689–e0122689. 3 indexed citations

12.

Seggewiss‐Bernhardt, Ruth, Ralf C. Bargou, Yeow Tee Goh, et al.. (2015). Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 121(13). 2185–2192. 52 indexed citations

13.

Nerreter, Thomas, et al.. (2014). Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. Experimental Hematology. 42(9). 773–782.e3. 9 indexed citations

14.

Stühmer, Thorsten, et al.. (2013). Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells. Leukemia & lymphoma. 55(1). 168–176. 19 indexed citations

15.

Juric, Dejan, Martin Schüler, Jordan Berlin, et al.. (2013). Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study. Cancer Research. 73(24_Supplement). P2–16. 12 indexed citations

16.

Nerreter, Thomas, et al.. (2013). Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro. Experimental Hematology. 41(7). 604–614.e4. 5 indexed citations

17.

Fiedler, Walter, M. Wolf, Maxim Kebenko, et al.. (2012). A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 2504–2504. 33 indexed citations

18.

Seystahl, Katharina, Doris Urlaub, Hermann Einsele, et al.. (2012). Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. International Journal of Cancer. 131(6). E916–27. 37 indexed citations

19.

Kreutzman, Anna, Taina Jaatinen, Dario Greco, et al.. (2012). Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Experimental Hematology. 40(11). 906–913.e1. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact